Study subjects
illness, fever, blood disorders, coagulopathy, chronic disease
BLOOD DISORDERS, INFLUENZA, ALLERGY TO EGGS, COAGULOPATHY, CHRONIC DISEASE, INFLUENZA
A total of 540 subjects were enrolled in this study. Subjects were enrolled from 3 primary care centers in Bandung City, Ibrahim Adjie Primary Health Center, Puter Primary Health Center, and Garuda Primary Health Center, from October 2017 to June 2018. The primary inclusion criteria included healthy children and adults aged 9–40 years who have signed the informed consent form and committed to complying with study instructions and trial schedules. Subjects were not eligible if the subject have enrolled or scheduled to be enrolled in another trial, presented with mild, moderate, or severe illness with a fever (axillary temperature ≥37.5⁰C), history of allergy to egg, chicken protein, or other vaccine, uncontrolled coagulopathy or blood disorders contraindicating intramuscular injection, received in the previous 4 weeks a treatment likely to alter the immune response [intravenous immunoglobulins, blood-derived products, or long-term corticosteroid therapy (>2 weeks)], pregnancy and lactation (adult), have any abnormality or chronic disease which according to the investigator might interfere with the assessment of the trial objectives, have already immunized with influenza vaccine within 1 year or any vaccination within 1 month before and after immunization of Quadrivalent Influenza Vaccine.